The Role of Endothelin in Pulmonary Hypertension

Brief Title

The Role of Endothelin in Pulmonary Hypertension

Official Title

The Role of Endothelin in Pulmonary Hypertension

Brief Summary

      The purpose of the study is is to determine the effect, on the lung circulation, of BQ-123,
      an investigational compound which is not approved by the FDA.
    

Detailed Description

      Endothelin levels are increased in patients with pulmonary hypertension. We wish to compare
      the effect of an endothelin antagonist on pulmonary hypertension due to a variety of causes.
    

Study Phase

Phase 2

Study Type

Interventional


Primary Outcome

Pulmonary Vascular Resistance (PVR)

Secondary Outcome

 Systemic Vascular Resistance (SVR)

Condition

Pulmonary Hypertension

Intervention

BQ-123

Study Arms / Comparison Groups

 1
Description:  BQ-123

Publications

* Includes publications given by the data provider as well as publications identified by National Clinical Trials Identifier (NCT ID) in Medline.

Recruitment Information


Recruitment Status

Drug

Estimated Enrollment

38

Start Date

February 1999

Completion Date

June 2011

Primary Completion Date

October 2010

Eligibility Criteria

        Inclusion Criteria:

          -  Healthy volunteers or known diagnosis of pulmonary hypertension

        Exclusion Criteria:

          -  hypertension due to other reasons (not pulmonary)
      

Gender

All

Ages

18 Years - 85 Years

Accepts Healthy Volunteers

Accepts Healthy Volunteers

Contacts

Mark A Creager, MD, , 

Location Countries

United States

Location Countries

United States

Administrative Informations


NCT ID

NCT00759408

Organization ID

1999-P-003126


Responsible Party

Principal Investigator

Study Sponsor

Brigham and Women's Hospital


Study Sponsor

Mark A Creager, MD, Principal Investigator, Brigham and Women's Hospital


Verification Date

November 2018